Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study
- Martín-Richard, M. 1
- Massutí, B. 2
- Pineda, E. 3
- Alonso, V. 4
- Marmol, M. 5
- Castellano, D. 6
- Fonseca, E. 7
- Galán, A. 8
- Llanos, M. 9
- Sala, M.A. 10
- Pericay, C. 11
- Rivera, F. 12
- Sastre, J. 13
- Segura, A. 14
- Quindós, M. 15
- Maisonobe, P. 16
-
1
Hospital de la Santa Creu i Sant Pau
info
-
2
Hospital General Universitario de Alicante
info
- 3 Medical Department, Ipsen Pharma
-
4
Hospital Miguel Servet
info
-
5
Hospital Clinic Barcelona
info
-
6
Hospital Universitario 12 de Octubre
info
-
7
Hospital Universitario de Salamanca
info
-
8
Hospital de Sagunto
info
-
9
Hospital Universitario de Canarias
info
-
10
Hospital Universitario de Basurto
info
- 11 Medical Oncology Department, Hospital Universitari de Sabadell, Corporació Sanitaria Universitaria Parc Tauli
-
12
Hospital Universitario Marqués de Valdecilla
info
-
13
Hospital Clínico San Carlos de Madrid
info
-
14
Hospital Universitario La Fe
info
- 15 Medical Oncology, Hospital A Coruña
- 16 Global Medical Affairs, Ipsen Pharma
Journal:
BMC Cancer
ISSN: 1471-2407
Year of publication: 2013
Volume: 13
Type: Article
DOI:
10.1186/1471-2407-13-427
PMID:
24053191
SCOPUS:
2-s2.0-84884315127
GOOGLE SCHOLAR
lock_openOpen access editor
Data source: Scopus